Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals has submitted a routine compliance certificate under SEBI's Depositories Regulations for the quarter ended September 30, 2025. The company's Registrar and Share Transfer Agent, KFIN Technologies Limited, confirmed that all dematerialisation requests received during July–September 2025 were processed within 15 days, physical certificates were mutilated and cancelled, and updated member records were sent to the depositories. Separate confirmations were filed with both CDSL and NSDL, with details furnished to the stock exchanges. The Managing Director Bharat Sharma signed and submitted the intimation to BSE (Scrip code: 539680) on October 9, 2025.
This is standard quarterly regulatory housekeeping with no material impact on the business, share price, or shareholder value. No new shares were issued or transferred — it only documents routine processing of existing share demat requests.